LRG1 Protein
Description
Product Specs
PEGLWASLGQ PNWDMRDGFD ISGNPWICDQ NLSDLYRWLQ AQKDKMFSQN DTRCAGPEAV KGQTLLAVAK SQ.
Product Science Overview
LRG1 is constitutively expressed by hepatocytes and neutrophils . It is involved in various biological processes, including:
- Positive regulation of transforming growth factor beta (TGFβ) receptor signaling pathway
- Positive regulation of endothelial cell proliferation and angiogenesis
- Neutrophil degranulation
- Brown fat cell differentiation
LRG1 has been shown to promote neovascularization (new blood vessel growth) by causing a switch in TGFβ signaling in endothelial cells. It binds to the accessory receptor endoglin and promotes signaling via the ALK1-Smad1/5/8 pathway .
Elevated levels of LRG1 have been observed in various pathological conditions, making it a potential biomarker and therapeutic target. Some of the conditions associated with increased LRG1 levels include:
- Acute appendicitis: LRG1 levels are markedly elevated and can be used as a diagnostic aid .
- Cancer: Circulating LRG1 levels are increased in many cancer patients. Inhibition of LRG1 normalizes tumor vasculature, improves the efficacy of cytotoxic and immune therapies, and restricts metastatic spread .
- Eye diseases, neurodegenerative diseases, diabetes, lung and kidney diseases: LRG1 has been implicated in the pathogenesis of these diseases .
LRG1 is considered a promising therapeutic target due to its role in pathological angiogenesis and disease progression. Inhibition of LRG1 through gene deletion or function-blocking antibodies has been shown to attenuate disease progression in animal studies . This makes LRG1 a potentially important factor in the development of new treatments for diseases characterized by aberrant neovascularization and inflammation .
